Mineralys Therapeutics, Inc.(MLYS)
$14.16+0.38 (+2.76%)
MLYS
Mineralys Therapeutics, Inc. financials statements
$14.16
At close:+0.38 (+2.76%)
Want to see MLYS full AI Analyst Report?
Mineralys Therapeutics, Inc. (MLYS) Ratios
614 Followers
Mineralys Therapeutics, Inc. Ratios
MLYS's free cash flow for Q3 2026 was $-43.10M. For the 2026 fiscal year, MLYS's free cash flow was increased by $0.00 and operating cash flow was $-43.10M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 43.76 | 14.02 | 23.76 | 13.98 | 2.20 |
| Quick Ratio | 43.76 | 14.02 | 23.76 | 13.98 | 2.20 |
| Cash Ratio | 11.44 | 7.79 | 4.70 | 10.87 | 2.10 |
| Solvency Ratio | -10.23 | -12.14 | -6.86 | -0.18 | -0.57 |
| Operating Cash Flow Ratio | -9.42 | -11.36 | -7.74 | -3.62 | -2.88 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 646.27M | $ 190.71M | $ 238.62M | $ -53.90M | $ -22.93M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.02 | 1.08 | 1.04 | -2.19 | -0.49 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | -18.78 | -717.81 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -18.78 | -693.52 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.32 | 0.01 |
| Net Debt to EBITDA | 1.12 | 0.64 | 0.58 | 2.79 | 0.55 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 90.65% | 92.42% | 84.93% | 94.66% | 103.65% |
| Return on Assets (ROA) | -23.37% | -86.36% | -28.57% | -26.04% | -174.45% |
| Return on Equity (ROE) | -23.91% | -92.97% | -29.81% | 57.01% | 84.66% |
| Return on Capital Employed (ROCE) | -26.38% | -100.60% | -35.10% | -29.59% | -308.43% |
| Return on Invested Capital (ROIC) | -26.38% | -100.60% | -35.10% | -29.59% | -308.43% |
| Return on Tangible Assets | -23.37% | -86.36% | -28.57% | -26.04% | -174.45% |
| Earnings Yield | -6.30% | -29.76% | -23.10% | -31.28% | -21.12% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.10 | -3.43 | -2.24 | -5.66 | -2.92 |
| Free Cash Flow Per Share | -2.11 | -3.43 | -2.24 | -5.66 | -2.92 |
| Dividend Paid and CapEx Coverage Ratio | -9494.40 | -1732.44 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | -9494.40 | -1732.44 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -5.80% | -27.85% | -26.08% | -30.67% | -15.84% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -15.85 | -3.36 | -4.33 | -3.20 | -4.74 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 3.80 | 3.12 | 1.29 | -1.82 | -4.01 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -17.24 | -3.59 | -3.83 | -3.26 | -6.31 |
| Price-to-Operating Cash Flow Ratio | -17.24 | -3.59 | -3.83 | -3.26 | -6.31 |
| Price-to-Earnings Growth (PEG) Ratio | 0.42 | -0.04 | 0.07 | -0.07 | -0.01 |
| Enterprise Value Multiple | -14.76 | -2.72 | -3.09 | -0.24 | -4.19 |
| Enterprise Value | 2.28B | 483.42M | 261.91M | 7.58M | 81.29M |
| EV to EBITDA | -14.76 | -2.72 | -3.09 | -0.24 | -4.19 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -16.02 | -2.91 | -3.23 | -0.26 | -5.58 |
| EV to Operating Cash Flow | -16.03 | -2.91 | -3.23 | -0.26 | -5.58 |
| Tangible Book Value Per Share | 9.56 | 3.94 | 6.66 | -10.12 | -4.60 |
| Shareholders’ Equity Per Share | 9.56 | 3.94 | 6.66 | -10.12 | -4.60 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -2.29 | -3.66 | -1.99 | -5.77 | -3.89 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.85 | 0.95 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.92 | 0.94 | 1.13 | 0.98 | 0.75 |
Currency in USD

